logo

Biotech stocks facing FDA Decision in June

Valeant Pharmaceuticals
Valeant Pharmaceuticals

Valeant Pharmaceuticals International Inc. (VRX) (VRX.TO) awaits the FDA approval for IDP-118 lotion, proposed as a topical treatment for plaque psoriasis, on June 18, 2018.

IDP-118 is a fixed combination of Halobetasol, a corticosteroid, and Tazarotene, a retinoid, formulated as a once-daily lotion.

According to the Company, IDP-118, with its dual mechanism of action, can achieve greater efficacy at a much lower concentration while reducing irritation in patients who use a corticosteroid-retinoid combination to treat psoriasis.

If approved, IDP-118 will be the first and only topical lotion that contains the unique combination of Halobetasol and Tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.

Valeant already has one marketed drug for patients with moderate-to-severe plaque psoriasis by the name SILIQ injection, for subcutaneous use, which was approved by the FDA last February.

VRX closed Friday’s (May 25) trading at $22.24, up 0.09%.

Share